TPD52 as a Therapeutic Target in Breast Cancer
Author Information
Author(s): Xia Jie, Zhou Xudong
Primary Institution: Tongji Medical College, Huazhong University of Science and Technology
Hypothesis
This study aims to elucidate the role of TPD52 as an immune regulator in breast cancer using machine learning methodologies.
Conclusion
TPD52 may serve as a promising biomarker for therapeutic intervention in breast cancer, influencing immune responses and patient prognosis.
Supporting Evidence
- TPD52 was identified as a hazardous marker associated with reduced survival rates in breast cancer patients.
- High TPD52 expression correlated with lower immune cell abundance in the tumor microenvironment.
- In vitro studies showed that reducing TPD52 expression decreased cancer cell proliferation and migration.
Takeaway
Researchers found that a protein called TPD52 affects how the immune system interacts with breast cancer, which could help doctors treat patients better.
Methodology
The study used single-cell RNA sequencing and machine learning techniques to analyze the immune landscape and identify differentially expressed genes related to TPD52.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website